Fighting Cancer with Precision Immunotherapy
Next-generation CAR-T therapies tailored to each patient’s immune system.
About Us
We combat the deadly progression of cancer using innovative, precision-based immunotherapy designed to improve outcomes and reduce side effects.
Led by Dr. Christopher E. Rudd, Immunab brings together world-class science and and translational expertise.
Our Solution
We design personalized CAR-T therapies that:
- Precisely target and eliminate tumors
- Are engineered from each patient’s unique immune profile
- Show 5–10x greater effectiveness in preclinical lymphoma models
How Does CAR-T
Cell Therapy Work?
Extract T-Cells
T cells are collected from the patient at the
clinic through a simple blood donation.
Modify in Lab
T cells are modified in the lab based on the
patient’s cancer type, stage, and immune
profile.
Reinject to Destroy Caner
Cancer is cleared or significantly reduced within weeks.
The Impact
Reduced side effects compared to chemotherapy and radiation
Accelerated and cost-efficient R&D pipeline
Demonstrated early success in melanoma and lymphoma
Pipeline
Discovery
Proof of Concept
Pre-Clinical
CAR-STAR1 – T-cell acute lymphoblastic leukemia (T-ALL) (GD3)
CAR-STAR2 – B-cell Acute Lymphoblastic Leukemia (B-ALL)(CD19)
CAR-STAR3 – Melanoma (CD3/CD19)
CAR-RASAL – Prostate cancer models
CAR-RASAL-STAR1 – Prostate cancer models
CAR-STAR1
T-cell acute lymphoblastic leukemia (T-ALL) (GD3)
Status: Proof of concept
CAR-STAR2
B-cell Acute Lymphoblastic Leukemia (B-ALL) (CD19)
Status: Proof of concept
CAR-STAR3
Melanoma (CD3/CD19)
Status: Proof of concept
CAR-RASAL
Prostate cancer models
Status: discovery
CAR-RASAL-STAR1
Prostate cancer models
Status: discovery